Page last updated: 2024-12-08

cyhalofop-butyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyhalofop-butyl: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID180089
CHEMBL ID1900438
CHEBI ID81863
SCHEMBL ID56020
MeSH IDM0486334

Synonyms (48)

Synonym
cyhalofop-butyl
122008-85-9
cyhalofop-butyl [iso]
xde 537
NCGC00168299-01
clincher
hsdb 7272
propanoic acid, 2-(4-(4-cyano-2-fluorophenoxy)phenoxy)-, butyl ester, (2r)-
butyl (2r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propanoate
butyl (2r)-2-[4-(4-cyano-2-fluoranyl-phenoxy)phenoxy]propanoate
(2r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propanoic acid butyl ester
A804822
NCGC00168299-02
(2r)-2-(4-(4-cyano-2-fluorophenoxy)-phenoxy)propanic acid butylester
ccris 9267
unii-18hgv9oc6g
(r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propionic acid butyl ester
C2417
butyl (r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propionate
cyhalofop butyl
C18607
dtxsid1034503 ,
cas-122008-85-9
tox21_301029
dtxcid9014503
NCGC00254931-01
18hgv9oc6g ,
AKOS015889006
SCHEMBL56020
cyhalofop butyl ester
(2r)-2-(4-(4-cyano-2-fluorophenoxy)phenoxy)propanoic acid butyl ester
cyhalofop-butyl [mi]
xde-537
cyhalofop-butyl [hsdb]
CHEBI:81863 ,
CHEMBL1900438
clincher; clincher ca;xde 537
J-004751
(r)-butyl 2-(4-(4-cyano-2-fluorophenoxy)phenoxy)propanoate
propanoic acid, 2-[4-(4-cyano-2-fluorophenoxy)phenoxy]-, butyl ester, (2r)-
cyhalofop-butyl, pestanal(r), analytical standard
mfcd01631151
cyhalofop-butyl 10 microg/ml in cyclohexane
Q27155630
xde537
BS-21239
CS-0012875
HY-B0861

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our results demonstrated that cyhalofop-butyl was highly toxic to zebrafish embryos, with concentration-dependent negative effects in embryonic development."( Cyhalofop-butyl has the potential to induce developmental toxicity, oxidative stress and apoptosis in early life stage of zebrafish (Danio rerio).
Chai, T; Mu, X; Qiu, L; Wang, C; Wang, K; Yang, Y; Zhu, L, 2015
)
2.15

Dosage Studied

HFFD3 was highly resistant to cyhalofop-butyl and exhibited cross-resistance to metamifop, fenoxaprop-P-ethyl. Whole-plant dose-response experiments showed that the resistance index (RI) of these R? RR, and RRR populations to cy Halfop-Butyl ranged from 2 to 4.

ExcerptRelevanceReference
" palustris under three dosage groups."( The removal of cyhalofop-butyl in soil by surplus Rhodopseudanonas palustris in wastewater purification.
Cao, B; Chen, Z; Cui, Y; Hou, Y; Jin, L; Li, N; Mo, W; Song, Y; Wang, Y; Wu, P; Zhang, Y; Zhu, F, 2019
)
0.87
" Dose-response tests indicated that five populations (JS3, JS4, JS6, JS7 and JS8) had evolved high-level resistance (26."( Molecular basis of resistance to ACCase-inhibiting herbicide cyhalofop-butyl in Chinese sprangletop (Leptochloa chinensis (L.) Nees) from China.
Cai, J; Chen, Y; Deng, W; Di, Y; Yuan, S; Zhang, J, 2019
)
0.76
" Dose-response bioassays revealed that HFFD3 was highly resistant to cyhalofop-butyl and exhibited cross-resistance to metamifop, fenoxaprop-P-ethyl, quizalofop-P-ethyl, and clethodim."( Cyhalofop-butyl resistance conferred by a novel Trp-2027-Leu mutation of acetyl-CoA carboxylase and enhanced metabolism in Leptochloa chinensis.
Cao, H; Gao, Q; Jiang, M; Li, Q; Liao, M; Zhang, J; Zhao, N, 2022
)
2.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency27.37070.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency27.37070.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency24.18810.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency24.71560.000221.22318,912.5098AID588516; AID743036; AID743054; AID743063
progesterone receptorHomo sapiens (human)Potency54.15040.000417.946075.1148AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.72960.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.13950.001530.607315,848.9004AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency31.62280.375827.485161.6524AID588527
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.37700.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency17.26980.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency15.84890.023723.228263.5986AID588541
thyroid stimulating hormone receptorHomo sapiens (human)Potency17.86600.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency4.30130.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (9.52)29.6817
2010's19 (45.24)24.3611
2020's19 (45.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.51 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index67.98 (26.88)
Search Engine Supply Index2.85 (0.95)

This Compound (36.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (97.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]